Illumina Radiopharmaceuticals LLC

This is a prospective Phase 2 study being performed to document the relationship between 18F-mIBG positron emission tomography (PET) findings in subjects, and expression of the norepinephrine transporter. In addition to collecting safety data for the imaging agent, the study aims to:
* compare the findings against other catacholamine transporters
* evaluate the imaging results at different time points and in different organs
* assess the quality of images with lower doses
* compare the ability to detect neuroblastoma lesions against other imaging agents, and in other tumors

This is a Phase 3 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for confirming or excluding the presence of neuroblastoma

This is a Phase 1/2 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for quantification of myocardial sympathetic innervation.